Aims and scope
Translational Neurodegeneration is an open access, peer-reviewed journal that covers research, therapeutics and education for all aspects of neurodegenerative diseases. By offering a high-visibility forum for new insights and discussions, Translational Neurodegeneration creates a novel interface between the fields of basic, translational, and clinical research. It includes Parkinson's disease and movement disorders, Alzheimer's disease and other dementias, motor neuron disease and other neurodegenerative diseases.
Topics of interest include but are not limited to the following areas of neurodegenerative diseases:
- Epidemiology and pathogenesis
- Research into diagnosis and prevention
- Research into the disease pathogenesis
- Development of new drugs and cell therapy
- Drug delivery
Translational Neurodegeneration offers the opportunity for scientists, clinicians and physician-scientists to publish their research and clinical trials in a journal which is applicable to their specific field.
All articles published by Translational Neurodegeneration are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here.
As authors of articles published in Translational Neurodegeneration you are the copyright holders of your article and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate your article, according to the BioMed Central license agreement.
For those of you who are US government employees or are prevented from being copyright holders for similar reasons, BioMed Central can accommodate non-standard copyright lines. Please contact us if further information is needed.
Open access publishing is not without costs. Translational Neurodegeneration therefore levies an article-processing charge of £1690.00/$2400.00/€2040.00 for each article accepted for publication, plus VAT or local taxes where applicable.
If the corresponding author's institution participates in our open access membership program, some or all of the publication cost may be covered (more details available on the membership page). We routinely waive charges for authors from low-income countries. For other countries, article-processing charge waivers or discounts are granted on a case-by-case basis to authors with insufficient funds. Authors can request a waiver or discount during the submission process. For further details, see our article-processing charge page.
BMC provides a free open access funding support service to help authors discover and apply for article processing charge funding. Visit our OA funding and policy support page to view our list of research funders and institutions that provide funding for APCs, and to learn more about our email support service.
All articles published in Translational Neurodegeneration are included in:
- PubMed Central
- Science Citation Index Expanded
The full text of all articles is deposited in digital archives around the world to guarantee long-term digital preservation. You can also access all articles published by BioMed Central on SpringerLink.
Translational Neurodegeneration operates a single-blind peer-review system, where the reviewers are aware of the names and affiliations of the authors, but the reviewer reports provided to authors are anonymous.
The benefit of single-blind peer review is that it is the traditional model of peer review that many reviewers are comfortable with, and it facilitates a dispassionate critique of a manuscript.
Edited by Shengdi Chen, Translational Neurodegeneration is supported by an expert Editorial Board. Manuscripts are reviewed by internationally recognized experts in the field, selected in part from the journal's Editorial Board. The suitability of manuscripts for publication is assessed solely on criteria of scientific excellence: final decisions are made by the Editor-in-Chief and may include accept, reject, accept following minor revision and resubmit after major revision and further review.
The editorial policies of Translational Neurodegeneration are determined jointly by its Editorial Board and Springer Nature in accordance with the legal and regulatory requirements of China. Unless otherwise stipulated in these guidelines, all manuscripts submitted to Translational Neurodegeneration should adhere to BioMed Central's editorial policies.
Citing articles in Translational Neurodegeneration
Articles in Translational Neurodegeneration should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number.
Article citations follow this format:
Authors: Title. Transl Neurodegener [year], [volume number]:[article number].
e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. Transl Neurodegener 2009, 1:115.
refers to article 115 from Volume 1 of the journal.
Appeals and complaints
If you wish to appeal a rejection or make a complaint you should, in the first instance, contact the Editor who will provide details of the journal's complaints procedure. For complaints that cannot be resolved with the Editor, the authors should contact the Publisher.
Why publish your article in Translational Neurodegeneration
Translational Neurodegeneration's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience.
Speed of publication
Translational Neurodegeneration offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles will be published with their final citation after acceptance, in both fully browsable web form, and as a formatted PDF.
Online publication in Translational Neurodegeneration gives you the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other articles).
Promotion and press coverage
Articles published in Translational Neurodegeneration are included in article alerts and regular email updates. Some may be highlighted on Translational Neurodegeneration’s pages and on the BioMed Central homepage.
In addition, articles published in Translational Neurodegeneration may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Translational Neurodegeneration. A list of articles recently press-released by journals published by BioMed Central is available here.
As an author of an article published in Translational Neurodegeneration you retain the copyright of your article and you are free to reproduce and disseminate your work (for further details, see the BioMed Central license agreement).
For further information about the advantages of publishing in a journal from BioMed Central, please click here.
2017 Journal Metrics
48 days to first decision for reviewed manuscripts only
46.5 days to first decision for all manuscripts
96.4 days from submission to acceptance
11.9 days from acceptance to publication
115 Altmetric mentions